Nektar Therapeutics/$NKTR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Ticker
$NKTR
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
61
ISIN
US6402681083
Website
NKTR Metrics
BasicAdvanced
$139M
-
-$0.63
0.63
-
Price and volume
Market cap
$139M
Beta
0.63
52-week high
$1.52
52-week low
$0.43
Average daily volume
1.9M
Financial strength
Current ratio
3.241
Quick ratio
3.107
Long term debt to equity
1,199.716
Total debt to equity
1,358.706
Interest coverage (TTM)
-5.07%
Management effectiveness
Return on assets (TTM)
-26.80%
Return on equity (TTM)
-189.46%
Valuation
Price to revenue (TTM)
1.794
Price to book
11.46
Price to tangible book (TTM)
11.46
Price to free cash flow (TTM)
-0.878
Growth
Revenue change (TTM)
-3.24%
Earnings per share change (TTM)
-30.92%
3-year revenue growth (CAGR)
-5.41%
3-year earnings per share growth (CAGR)
-38.01%
What the Analysts think about NKTR
Analyst ratings (Buy, Hold, Sell) for Nektar Therapeutics stock.
NKTR Financial Performance
Revenues and expenses
NKTR Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nektar Therapeutics stock?
Nektar Therapeutics (NKTR) has a market cap of $139M as of June 05, 2025.
What is the P/E ratio for Nektar Therapeutics stock?
The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of June 05, 2025.
Does Nektar Therapeutics stock pay dividends?
No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of June 05, 2025.
When is the next Nektar Therapeutics dividend payment date?
Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.
What is the beta indicator for Nektar Therapeutics?
Nektar Therapeutics (NKTR) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.